How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Sell
45
PHG Quote, Financials, Valuation and Earnings
Last price:
$25.39
Seasonality move
:
1.49%
Day range:
$25.06 - $25.48
52-week range:
$19.10 - $32.91
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.24x
P/B ratio:
1.90x
Volume:
815.2K
Avg. volume:
951.4K
1-year change:
32.58%
Market cap:
$23.7B
Revenue:
$19.5B
EPS (TTM):
-$0.79
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PHG
Koninklijke Philips NV
|
$4.4B | $0.17 | -1.1% | 1063.59% | $33.00 |
|
ARGX
argenx SE
|
$814.7M | $2.11 | 104.07% | -44.75% | $763.30 |
|
MRUS
Merus NV
|
$6.9M | -$1.08 | 2.89% | -74.43% | $87.20 |
|
PHAR
Pharming Group
|
$64.1M | -$0.03 | 15.36% | -86.84% | $30.00 |
|
PRQR
ProQR Therapeutics NV
|
$4.9M | -$0.16 | 1.34% | -63.67% | $10.67 |
|
QURE
uniQure NV
|
$6.4M | -$1.04 | -27.53% | -27.05% | $35.86 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PHG
Koninklijke Philips NV
|
$25.64 | $33.00 | $23.7B | -- | $0.00 | 0% | 1.24x |
|
ARGX
argenx SE
|
$591.87 | $763.30 | $36.1B | 46.57x | $0.00 | 0% | 16.97x |
|
MRUS
Merus NV
|
$44.61 | $87.20 | $3.1B | -- | $0.00 | 0% | 79.27x |
|
PHAR
Pharming Group
|
$8.31 | $30.00 | $563.7M | -- | $0.00 | 0% | 1.98x |
|
PRQR
ProQR Therapeutics NV
|
$1.40 | $10.67 | $147.3M | -- | $0.00 | 0% | 5.90x |
|
QURE
uniQure NV
|
$12.47 | $35.86 | $674.3M | -- | $0.00 | 0% | 22.37x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PHG
Koninklijke Philips NV
|
34.84% | -0.478 | 28.47% | 0.80x |
|
ARGX
argenx SE
|
-- | 1.058 | -- | 6.40x |
|
MRUS
Merus NV
|
-- | 0.089 | -- | 6.22x |
|
PHAR
Pharming Group
|
27.08% | -2.475 | 12.07% | 3.02x |
|
PRQR
ProQR Therapeutics NV
|
4.92% | -0.382 | 1.71% | 3.89x |
|
QURE
uniQure NV
|
115.15% | -6.920 | 5.93% | 9.32x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PHG
Koninklijke Philips NV
|
$2.1B | $195.1M | -4.08% | -5.84% | 3.41% | -- |
|
ARGX
argenx SE
|
$665.8M | $101.6M | 18.03% | 21.33% | 11.81% | -$147M |
|
MRUS
Merus NV
|
-- | -$88.7M | -38.4% | -38.4% | -969.93% | -$66.7M |
|
PHAR
Pharming Group
|
$80.5M | $6.6M | -3.37% | -5.03% | 9.86% | $9.2M |
|
PRQR
ProQR Therapeutics NV
|
-- | -$10.7M | -57.21% | -62.97% | -150.73% | -$9.8M |
|
QURE
uniQure NV
|
$4.6M | -$42.5M | -131.71% | -239.27% | -1101.88% | -$52.9M |
Koninklijke Philips NV vs. Competitors
-
Which has Higher Returns PHG or ARGX?
argenx SE has a net margin of -6.64% compared to Koninklijke Philips NV's net margin of 15.95%. Koninklijke Philips NV's return on equity of -5.84% beat argenx SE's return on equity of 21.33%.
Company Gross Margin Earnings Per Share Invested Capital PHGKoninklijke Philips NV38.92% -$0.38 $19.2B ARGXargenx SE90.16% $11.87 $5.5B -
What do Analysts Say About PHG or ARGX?
Koninklijke Philips NV has a consensus price target of $33.00, signalling upside risk potential of 28.71%. On the other hand argenx SE has an analysts' consensus of $763.30 which suggests that it could grow by 28.97%. Given that argenx SE has higher upside potential than Koninklijke Philips NV, analysts believe argenx SE is more attractive than Koninklijke Philips NV.
Company Buy Ratings Hold Ratings Sell Ratings PHGKoninklijke Philips NV1 1 0 ARGXargenx SE13 2 0 -
Is PHG or ARGX More Risky?
Koninklijke Philips NV has a beta of 0.778, which suggesting that the stock is 22.205% less volatile than S&P 500. In comparison argenx SE has a beta of 0.597, suggesting its less volatile than the S&P 500 by 40.308%.
-
Which is a Better Dividend Stock PHG or ARGX?
Koninklijke Philips NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Koninklijke Philips NV pays -0.14% of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHG or ARGX?
Koninklijke Philips NV quarterly revenues are $5.4B, which are larger than argenx SE quarterly revenues of $738.4M. Koninklijke Philips NV's net income of -$357.1M is lower than argenx SE's net income of $774.2M. Notably, Koninklijke Philips NV's price-to-earnings ratio is -- while argenx SE's PE ratio is 46.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Koninklijke Philips NV is 1.24x versus 16.97x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHGKoninklijke Philips NV1.24x -- $5.4B -$357.1M ARGXargenx SE16.97x 46.57x $738.4M $774.2M
-
Which has Higher Returns PHG or MRUS?
Merus NV has a net margin of -6.64% compared to Koninklijke Philips NV's net margin of -338.33%. Koninklijke Philips NV's return on equity of -5.84% beat Merus NV's return on equity of -38.4%.
Company Gross Margin Earnings Per Share Invested Capital PHGKoninklijke Philips NV38.92% -$0.38 $19.2B MRUSMerus NV-- -$0.41 $647.9M -
What do Analysts Say About PHG or MRUS?
Koninklijke Philips NV has a consensus price target of $33.00, signalling upside risk potential of 28.71%. On the other hand Merus NV has an analysts' consensus of $87.20 which suggests that it could grow by 95.47%. Given that Merus NV has higher upside potential than Koninklijke Philips NV, analysts believe Merus NV is more attractive than Koninklijke Philips NV.
Company Buy Ratings Hold Ratings Sell Ratings PHGKoninklijke Philips NV1 1 0 MRUSMerus NV13 0 0 -
Is PHG or MRUS More Risky?
Koninklijke Philips NV has a beta of 0.778, which suggesting that the stock is 22.205% less volatile than S&P 500. In comparison Merus NV has a beta of 1.151, suggesting its more volatile than the S&P 500 by 15.128%.
-
Which is a Better Dividend Stock PHG or MRUS?
Koninklijke Philips NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Koninklijke Philips NV pays -0.14% of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHG or MRUS?
Koninklijke Philips NV quarterly revenues are $5.4B, which are larger than Merus NV quarterly revenues of $9.1M. Koninklijke Philips NV's net income of -$357.1M is lower than Merus NV's net income of -$30.9M. Notably, Koninklijke Philips NV's price-to-earnings ratio is -- while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Koninklijke Philips NV is 1.24x versus 79.27x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHGKoninklijke Philips NV1.24x -- $5.4B -$357.1M MRUSMerus NV79.27x -- $9.1M -$30.9M
-
Which has Higher Returns PHG or PHAR?
Pharming Group has a net margin of -6.64% compared to Koninklijke Philips NV's net margin of 3.99%. Koninklijke Philips NV's return on equity of -5.84% beat Pharming Group's return on equity of -5.03%.
Company Gross Margin Earnings Per Share Invested Capital PHGKoninklijke Philips NV38.92% -$0.38 $19.2B PHARPharming Group86.82% $0.06 $304.3M -
What do Analysts Say About PHG or PHAR?
Koninklijke Philips NV has a consensus price target of $33.00, signalling upside risk potential of 28.71%. On the other hand Pharming Group has an analysts' consensus of $30.00 which suggests that it could grow by 261.01%. Given that Pharming Group has higher upside potential than Koninklijke Philips NV, analysts believe Pharming Group is more attractive than Koninklijke Philips NV.
Company Buy Ratings Hold Ratings Sell Ratings PHGKoninklijke Philips NV1 1 0 PHARPharming Group2 0 0 -
Is PHG or PHAR More Risky?
Koninklijke Philips NV has a beta of 0.778, which suggesting that the stock is 22.205% less volatile than S&P 500. In comparison Pharming Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PHG or PHAR?
Koninklijke Philips NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Koninklijke Philips NV pays -0.14% of its earnings as a dividend. Pharming Group pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHG or PHAR?
Koninklijke Philips NV quarterly revenues are $5.4B, which are larger than Pharming Group quarterly revenues of $92.7M. Koninklijke Philips NV's net income of -$357.1M is lower than Pharming Group's net income of $3.7M. Notably, Koninklijke Philips NV's price-to-earnings ratio is -- while Pharming Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Koninklijke Philips NV is 1.24x versus 1.98x for Pharming Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHGKoninklijke Philips NV1.24x -- $5.4B -$357.1M PHARPharming Group1.98x -- $92.7M $3.7M
-
Which has Higher Returns PHG or PRQR?
ProQR Therapeutics NV has a net margin of -6.64% compared to Koninklijke Philips NV's net margin of -216.04%. Koninklijke Philips NV's return on equity of -5.84% beat ProQR Therapeutics NV's return on equity of -62.97%.
Company Gross Margin Earnings Per Share Invested Capital PHGKoninklijke Philips NV38.92% -$0.38 $19.2B PRQRProQR Therapeutics NV-- -$0.10 $96.9M -
What do Analysts Say About PHG or PRQR?
Koninklijke Philips NV has a consensus price target of $33.00, signalling upside risk potential of 28.71%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $10.67 which suggests that it could grow by 661.91%. Given that ProQR Therapeutics NV has higher upside potential than Koninklijke Philips NV, analysts believe ProQR Therapeutics NV is more attractive than Koninklijke Philips NV.
Company Buy Ratings Hold Ratings Sell Ratings PHGKoninklijke Philips NV1 1 0 PRQRProQR Therapeutics NV5 0 0 -
Is PHG or PRQR More Risky?
Koninklijke Philips NV has a beta of 0.778, which suggesting that the stock is 22.205% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.244, suggesting its less volatile than the S&P 500 by 75.592%.
-
Which is a Better Dividend Stock PHG or PRQR?
Koninklijke Philips NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Koninklijke Philips NV pays -0.14% of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHG or PRQR?
Koninklijke Philips NV quarterly revenues are $5.4B, which are larger than ProQR Therapeutics NV quarterly revenues of $4.6M. Koninklijke Philips NV's net income of -$357.1M is lower than ProQR Therapeutics NV's net income of -$9.9M. Notably, Koninklijke Philips NV's price-to-earnings ratio is -- while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Koninklijke Philips NV is 1.24x versus 5.90x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHGKoninklijke Philips NV1.24x -- $5.4B -$357.1M PRQRProQR Therapeutics NV5.90x -- $4.6M -$9.9M
-
Which has Higher Returns PHG or QURE?
uniQure NV has a net margin of -6.64% compared to Koninklijke Philips NV's net margin of -1403.2%. Koninklijke Philips NV's return on equity of -5.84% beat uniQure NV's return on equity of -239.27%.
Company Gross Margin Earnings Per Share Invested Capital PHGKoninklijke Philips NV38.92% -$0.38 $19.2B QUREuniQure NV88.14% -$1.50 $44.6M -
What do Analysts Say About PHG or QURE?
Koninklijke Philips NV has a consensus price target of $33.00, signalling upside risk potential of 28.71%. On the other hand uniQure NV has an analysts' consensus of $35.86 which suggests that it could grow by 187.6%. Given that uniQure NV has higher upside potential than Koninklijke Philips NV, analysts believe uniQure NV is more attractive than Koninklijke Philips NV.
Company Buy Ratings Hold Ratings Sell Ratings PHGKoninklijke Philips NV1 1 0 QUREuniQure NV8 2 0 -
Is PHG or QURE More Risky?
Koninklijke Philips NV has a beta of 0.778, which suggesting that the stock is 22.205% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.568%.
-
Which is a Better Dividend Stock PHG or QURE?
Koninklijke Philips NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Koninklijke Philips NV pays -0.14% of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PHG or QURE?
Koninklijke Philips NV quarterly revenues are $5.4B, which are larger than uniQure NV quarterly revenues of $5.2M. Koninklijke Philips NV's net income of -$357.1M is lower than uniQure NV's net income of -$73.3M. Notably, Koninklijke Philips NV's price-to-earnings ratio is -- while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Koninklijke Philips NV is 1.24x versus 22.37x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PHGKoninklijke Philips NV1.24x -- $5.4B -$357.1M QUREuniQure NV22.37x -- $5.2M -$73.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Raymond James Stock a Buy, Sell or Hold?
Raymond James Financial (NYSE:RJF) is one of America’s large financial…
Is JHX Stock a Buy Sell or Hold?
James Hardie Industries (NYSE:JHX) is a manufacturer of outside building…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
80
CORT alert for Apr 1
Corcept Therapeutics [CORT] is up 109.21% over the past day.
Sell
40
RGC alert for Mar 31
Regencell Bioscience Holdings [RGC] is up 26.1% over the past day.
Buy
74
COOP alert for Apr 1
Mr. Cooper Group [COOP] is up 14.4% over the past day.
